Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin

Dmitri Rozanov, Vladislav S. Golubkov, Alex Y. Strongin

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Protective antigen (PA) and lethal factor (LF) are the two components of anthrax lethal toxin. PA is responsible for interacting with cell receptors and for the subsequent translocation of LF inside the cell compartment. A re-engineered toxin comprised of PA and a fusion chimera LF/Pseudomonas exotoxin (FP59) is a promising choice for tumor cell surface targeting. We demonstrated, however, that in vitro in cell-free system and in cultured human colon carcinoma LoVo, fibrosarcoma HT1080 and glioma U251 cells membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves both the PA83 precursor and the PA63 mature protein. Exhaustive MT1-MMP cleavage of PA83 in vitro generates several major degradation fragments with an N-terminus at Glu40, Leu48, and Gln512. In cultured cells, MT1-MMP-dependent cleavage releases the cell-bound PA83 and PA63 species from the cell surface. As a result, MT1-MMP expressing cells have less PA63 to internalize. In agreement, our observations demonstrate that MT1-MMP proteolysis of PA makes the MT1-MMP-expressing aggressive invasive cells resistant to the cytotoxic effect of a bipartite PA/FP59 toxin. We infer from our studies that synthetic inhibitors of MMPs are likely to increase the therapeutic anti-cancer effect of anthrax toxin. In addition, our study supports a unique role of furin in the activation of PA, thereby suggesting that furin inhibitors are the likely specific drugs for short-term therapy of anthrax infection.

Original languageEnglish (US)
Pages (from-to)142-154
Number of pages13
JournalInternational Journal of Biochemistry and Cell Biology
Volume37
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 14
Antigens
Furin
Cells
Proteolysis
Exotoxins
Anthrax
Matrix Metalloproteinase Inhibitors
Cell-Free System
Fibrosarcoma
Cell membranes
Pseudomonas
anthrax toxin
Glioma
Tumors
Cultured Cells
Neoplasms
Colon
Fusion reactions
Chemical activation

Keywords

  • DMEM
  • Dulbecco's MEM
  • edema factor
  • EF
  • FP59
  • fusion protein 59 (a chimera in which LF residues 1-254 have been fused with the ADP-ribosylation domain III of Pseudomonas exotoxin A)
  • lethal factor
  • LF
  • lysis buffer

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin. / Rozanov, Dmitri; Golubkov, Vladislav S.; Strongin, Alex Y.

In: International Journal of Biochemistry and Cell Biology, Vol. 37, No. 1, 01.2005, p. 142-154.

Research output: Contribution to journalArticle

@article{7814496271be496a8add5305d44a2a3c,
title = "Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin",
abstract = "Protective antigen (PA) and lethal factor (LF) are the two components of anthrax lethal toxin. PA is responsible for interacting with cell receptors and for the subsequent translocation of LF inside the cell compartment. A re-engineered toxin comprised of PA and a fusion chimera LF/Pseudomonas exotoxin (FP59) is a promising choice for tumor cell surface targeting. We demonstrated, however, that in vitro in cell-free system and in cultured human colon carcinoma LoVo, fibrosarcoma HT1080 and glioma U251 cells membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves both the PA83 precursor and the PA63 mature protein. Exhaustive MT1-MMP cleavage of PA83 in vitro generates several major degradation fragments with an N-terminus at Glu40, Leu48, and Gln512. In cultured cells, MT1-MMP-dependent cleavage releases the cell-bound PA83 and PA63 species from the cell surface. As a result, MT1-MMP expressing cells have less PA63 to internalize. In agreement, our observations demonstrate that MT1-MMP proteolysis of PA makes the MT1-MMP-expressing aggressive invasive cells resistant to the cytotoxic effect of a bipartite PA/FP59 toxin. We infer from our studies that synthetic inhibitors of MMPs are likely to increase the therapeutic anti-cancer effect of anthrax toxin. In addition, our study supports a unique role of furin in the activation of PA, thereby suggesting that furin inhibitors are the likely specific drugs for short-term therapy of anthrax infection.",
keywords = "DMEM, Dulbecco's MEM, edema factor, EF, FP59, fusion protein 59 (a chimera in which LF residues 1-254 have been fused with the ADP-ribosylation domain III of Pseudomonas exotoxin A), lethal factor, LF, lysis buffer",
author = "Dmitri Rozanov and Golubkov, {Vladislav S.} and Strongin, {Alex Y.}",
year = "2005",
month = "1",
doi = "10.1016/j.biocel.2004.06.005",
language = "English (US)",
volume = "37",
pages = "142--154",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin

AU - Rozanov, Dmitri

AU - Golubkov, Vladislav S.

AU - Strongin, Alex Y.

PY - 2005/1

Y1 - 2005/1

N2 - Protective antigen (PA) and lethal factor (LF) are the two components of anthrax lethal toxin. PA is responsible for interacting with cell receptors and for the subsequent translocation of LF inside the cell compartment. A re-engineered toxin comprised of PA and a fusion chimera LF/Pseudomonas exotoxin (FP59) is a promising choice for tumor cell surface targeting. We demonstrated, however, that in vitro in cell-free system and in cultured human colon carcinoma LoVo, fibrosarcoma HT1080 and glioma U251 cells membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves both the PA83 precursor and the PA63 mature protein. Exhaustive MT1-MMP cleavage of PA83 in vitro generates several major degradation fragments with an N-terminus at Glu40, Leu48, and Gln512. In cultured cells, MT1-MMP-dependent cleavage releases the cell-bound PA83 and PA63 species from the cell surface. As a result, MT1-MMP expressing cells have less PA63 to internalize. In agreement, our observations demonstrate that MT1-MMP proteolysis of PA makes the MT1-MMP-expressing aggressive invasive cells resistant to the cytotoxic effect of a bipartite PA/FP59 toxin. We infer from our studies that synthetic inhibitors of MMPs are likely to increase the therapeutic anti-cancer effect of anthrax toxin. In addition, our study supports a unique role of furin in the activation of PA, thereby suggesting that furin inhibitors are the likely specific drugs for short-term therapy of anthrax infection.

AB - Protective antigen (PA) and lethal factor (LF) are the two components of anthrax lethal toxin. PA is responsible for interacting with cell receptors and for the subsequent translocation of LF inside the cell compartment. A re-engineered toxin comprised of PA and a fusion chimera LF/Pseudomonas exotoxin (FP59) is a promising choice for tumor cell surface targeting. We demonstrated, however, that in vitro in cell-free system and in cultured human colon carcinoma LoVo, fibrosarcoma HT1080 and glioma U251 cells membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves both the PA83 precursor and the PA63 mature protein. Exhaustive MT1-MMP cleavage of PA83 in vitro generates several major degradation fragments with an N-terminus at Glu40, Leu48, and Gln512. In cultured cells, MT1-MMP-dependent cleavage releases the cell-bound PA83 and PA63 species from the cell surface. As a result, MT1-MMP expressing cells have less PA63 to internalize. In agreement, our observations demonstrate that MT1-MMP proteolysis of PA makes the MT1-MMP-expressing aggressive invasive cells resistant to the cytotoxic effect of a bipartite PA/FP59 toxin. We infer from our studies that synthetic inhibitors of MMPs are likely to increase the therapeutic anti-cancer effect of anthrax toxin. In addition, our study supports a unique role of furin in the activation of PA, thereby suggesting that furin inhibitors are the likely specific drugs for short-term therapy of anthrax infection.

KW - DMEM

KW - Dulbecco's MEM

KW - edema factor

KW - EF

KW - FP59

KW - fusion protein 59 (a chimera in which LF residues 1-254 have been fused with the ADP-ribosylation domain III of Pseudomonas exotoxin A)

KW - lethal factor

KW - LF

KW - lysis buffer

UR - http://www.scopus.com/inward/record.url?scp=4644371786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644371786&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2004.06.005

DO - 10.1016/j.biocel.2004.06.005

M3 - Article

VL - 37

SP - 142

EP - 154

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

IS - 1

ER -